FDA Relaxing Restrictions on GSK’s Controversial Diabetes Drug Avandia

$25.00
Three years after placing heavy restrictions on GlaxoSmithKline’s type 2 diabetes drug Avandia, the FDA said Nov. 25 it is relaxing those restrictions in line with its advisers’ recommendations.